Replies to post #102745 on Biotech Values

[AlpineBV_Miller]

From a practical standpoint, the two phrases mean essentially the same thing.

They actually don't in cases where newer therapies increase tolerability and have higher therapeutic indexes. Proving either is not necessarily a quicker path to approval. The difference between the two phrases is likely to grow over time (couple decades) as pharmacoeconomics works into the equation.